The role of SRY-related high-mobility-group box (SOX) 12 in leukaemia progression and haematopoiesis remains elusive. This study aimed to examine the expression and function of SOX12 in acute myeloid leukaemia (AML) using human myeloid leukaemia samples and the acute myeloid cell line THP1. Mononuclear cells were isolated from the bone marrow of AML patients and healthy donors. SOX12 expression in haematopoietic cells was evaluated by reverse transcription polymerase chain reaction (RT-PCR). SOX12 short hairpin RNAs (shRNAs) were transduced into THP1 cells, and gene knockdown was confirmed by quantitative RT-PCR and Western blot analysis. SOX12 was preferentially expressed in CD34 + cells in AML patients. The THP1 cells transduced with SOX12 shRNAs exhibited significantly reduced SOX12 expression and cell proliferation. SOX12 knockdown had no effect on apoptosis, but it induced cell cycle arrest at G1 phase and reduced the number of colonies. The transduced THP1 and primary AML cells were reconstituted in non-obese diabetic-severe combined immunodeficient (NOD/SCID) mice, and their numbers were significantly reduced 6-12 weeks after transplantation. The mRNA and protein levels of b-catenin were significantly diminished following SOX12 knockdown, accompanied by a decrease in TCF/Wnt activity. SOX12 may be involved in leukaemia progression by regulating the expression of b-catenin and then interfering with TCF/Wnt pathway, which may be a target for AML.
Acute myeloid leukaemia (AML) is maintained by leukaemia-initiating cells (LICs), which can promote leukaemia in immunocompromised mice (Lapidot et al, 1996; Buzzeo et al, 2007; Taussig et al, 2010) . Various transcription factors participate in regulating the initiation, function and destiny of LICs in AML (Heuser et al, 2009; Zhang et al, 2013) . Novel treatments for AML that target the aberrant transcription machinery are potentially effective (Fuchs, 2010; Oellerich et al, 2015) . However, the functions and activities of most transcription factors in the LICs of AML remain elusive. Therefore, the identification of abnormal transcription factors and their functions in LICs could provide insights into the pathogenesis and treatment of AML.
SRY-related high-mobility group box (SOX) genes, encoding a family of transcription factors with a high-mobility group box domain, can bind to DNA in a sequence-specific manner and have been highly conserved throughout evolution (Sinclair et al, 1990; Lefebvre et al, 2007) . The SOX genes can be subdivided into 9 groups. To date, at least 30 members of this family have been identified and they can be expressed in various cell types and tissues at multiple stages of development (Prior & Walter, 1996; Pevny & LovellBadge, 1997; Schepers et al, 2002) . Each SOX gene can induce distinctive changes in transcription by partnering with different transcription factors, accounting for the diverse range of genes that are regulated by this gene family. Previous studies have shown that SOX genes function in the selfrenewal and multi-potency of stem cells (Bylund et al, 2003; Graham et al, 2003; Wang et al, 2006; Seymour et al, 2007) , thus potentially playing important roles in haematopoiesis (Sandoval et al, 2012; Nakajima-Takagi et al, 2013) , carcinogenesis (de la Rocha et al, 2014; Stovall et al, 2014) and leukaemogeneis (Man et al, 2015) .
The C subgroup of the SOX superfamily includes SOX4, SOX11 and SOX12 (Dy et al, 2008) . SOX4 plays an important role in normal haematopoiesis (Sandoval et al, 2012) , research paper and its expression is elevated in a wide variety of leukaemias, suggesting a fundamental role in the development of these malignancies (Zhang et al, 2013; Ramezani-Rad et al, 2013; Aue et al, 2011; Higuchi et al, 2013; Ma et al, 2014) . SOX11 has been implicated in lymphoma and chronic lymphoblastic leukaemia (Meggendorfer et al, 2013; Vegliante et al, 2013; Roisman et al, 2015) . SOX12, which was previously named SOX22, is expressed in various fetal and adult organs and tissues, supporting its roles in both the differentiation and maintenance of several cell types (Jay et al, 1997) . SOX4 and SOX11 can compensate for the function of SOX12 during development (Hoser et al, 2008) . SOX12 is involved in the developmental defects resulting from the 20p13 microdeletion . As the direct target of FOXQ1, SOX12 may promote hepatocellular carcinoma metastasis (Huang et al, 2015) . However, the role of SOX12 in haematopoiesis and leukaemia remains unknown.
The functions of the SOX genes are largely mediated through the Wnt/b-catenin (also termed WNT/CTNNB1) pathway via the regulation of b-catenin expression or binding to Wnt target gene promoters to modulate protein stability and nuclear translocation (Kormish et al, 2010; Aksoy et al, 2013; Man et al, 2015) . Dysregulation of the Wnt/b-catenin pathway has been observed in various malignancies, including AML (Wang et al, 2010) . The expression of b-catenin, one of the most important factors in the Wnt pathway, is up-regulated in AML, representing an independent adverse prognostic factor for this disease (Simon et al, 2005; Ysebaert et al, 2006) .
Our study examined the expression profile of SOX12 in AML and normal bone marrow, as well as the function and pathogenesis of SOX12 in AML.
Materials and methods

Sample collection, processing and cell culture
Bone marrow samples from patients at diagnosis or relapse with blast levels varying from 50% to 95%, and healthy donors were retrospectively collected with institutional approval in accordance with the Declaration of Helsinki. Mononuclear cells were isolated by density gradient centrifugation (Ficoll-Paque Plus, Amersham Biosciences, Uppsala, Sweden 
Cell lines
The cell lines, derived from human AML (THP1) were obtained from ATCC (Manassas, VA, USA) and grown in RPMI containing 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA). The HEK293FT cells used for lentivirus production were grown in DMEM containing 10% FBS and 1% PenStrep (100 u/ ml penicillin and 100 lg/ml streptomycin) (Invitrogen).
Reverse transcription polymerase chain reaction (RT-PCR) and quantitative RT-PCR (RT-qPCR)
Total RNA was extracted from bone marrow mononuclear cells (BMMNCs) from leukaemia patients or cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA was reverse-transcribed with Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). The expression of SOX12 was examined by gene-specific RT-qPCR (Applied Biosystems, Foster City, CA, USA). b-actin (ACTB) was used as the internal control (Table I) .
Plasmid preparation, lentivirus packaging and leukaemia cell transduction
The short hairpin RNAs (shRNAs) and scrambled control were designed and synthesized by Biobuffer Biotech (Wuhan, China) and ligated into the PLVX lentiviral vector (Biobuffer Biotech). Approximately 6 9 10 6 293FT cells were transfected with 10 lg of CMVD9, 2Á5 lg of PUDG and 5 lg of the lentiviral plasmids using Lipofectamine 2000 (Invitrogen). The target sequences are shown in Table I . After 48 or 72 h, the medium from three flasks of transfected 293FT cells was pooled, filtered with a 0Á45-lm syringe filter and ultracentrifuged at 37,000 rpm (Beckman Optima ™ XL-80K, Brea, CA, USA) for two hours. The supernatant was discarded, and the virus particles were resuspended in 200 ll of OPTI-MEM â I medium (Gibco, Grand Island, NY, USA), separated into 20 ll aliquots, and stored at À80°C for future use. During viral transduction, 0Á1-0Á5 9 10 6 leukaemia cells (CD34 + CD33 + AML or THP1 cells) were seeded in 24-well plates. The viral supernatant was added directly to the cells in the presence of polybrene (8 lg/ml, Sigma, St. Louis, MO, USA), followed by incubation at 37°C for 18 h. The cells were then washed and resuspended in 500 ll of culture medium and incubated at 37°C with 5% CO2 for 2 days before being subjected to FACS for analysis or sorting.
Western blotting
To evaluate SOX12 and b-catenin protein expression, proteins extracted from the THP1 cell line were separated by a 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane and blotted with mouse polyclonal anti-SOX12 (1:1000) (4A7, Sigma), mouse monoclonal anti-total b-catenin (1:500) (13-8400, Invitrogen) or mouse monoclonal anti-b-actin (1:10000) (A1978, Sigma) antibodies. The membranes were visualized using the Chemiluminescent Substrate method with the SuperSignal West Pico kit (Pierce Biotechnology, Inc., Rockford, IL, USA) and developed using X-ray film.
Colony forming unit assay
The clonogenic assay was performed by plating the transduced THP1 cells in 35-mm tissue culture plates in triplicate at 1Á0 9 10 3 cells/ml in MethoCult GF H4330 supplemented with 10% FBS (Stem Cell Technologies, Vancouver, BC, Canada). The colonies were enumerated on day 13 after culture at 37°C in a 5% CO 2 humidified incubator.
Cell proliferation, apoptosis and cell cycle analysis
To assess cell proliferation, 0Á1 9 10 6 transduced THP1 cells were incubated in 200 ll of 925 kBq/ml 3 [H] thymidine in culture medium for 18 h. The cells were applied to a Cytostar-T Scintillating microplate (Perkin Elmer, Waltham, MA, USA). The plate was then dried overnight at 55°C. The scintillant was added to the microplate on the following day, and the counts per minute were recorded using Top Count NXT (Perkin Elmer, Waltham, MA, USA).
To analyse the cell cycle, 0Á1 9 10 6 transduced THP1 cells were fixed with 70% v/v ethanol for 30 min at room temperature, followed by staining with a propidium iodide (PI) solution (40 lg/ml PI and 40 lg/ml RNaseA, Sigma) for 45 min in the dark. The samples were subjected to flow cytometry analysis within one hour. Apoptosis was examined using standard Annexin V/7-aminoactinomycin D (7-AAD) assays according to the manufacturer's instructions (Promega, Madison, WI, USA).
TOP/FlASH dual luciferase assay
Approximately 0Á5 9 10 6 scramble-and shRNA2-transduced 
Statistical analysis
Differences in the data between groups were analysed by 2-tailed paired or unpaired t-tests for numerical data (SPSS, Chicago, IL, USA). All statistical data are presented as the meanAEstandard error of the mean, unless stated otherwise. Each experiment was repeated at least three times, and representative data are shown. P-values less than 0Á05 were considered statistically significant.
Results
SOX12 was highly expressed in the BMMNCs of patients with AML
In an initial screen, the expression of SOX12 was examined in primary BMMNCs samples from patients with AML (n = 14) and healthy donors (n = 14) by RT-qPCR (Fig 1) . SOX12 was highly expressed in the BMMNCs of most AML samples, but it was expressed at low levels or was nearly absent in normal BMMNCs (P < 0Á0001) (Fig 1) .
SOX12 was highly expressed in CD34 + AML cells
The clonogenic potential of AML cells is limited to CD34 + cells (Yin et al, 1993) . To evaluate the expression of SOX12, CD34 + and CD34 À AML cells were purified with magnetic beads, and the expression of SOX12 in the two groups was 
SOX12 knockdown in THP1 cells reduced proliferation without affecting cell apoptosis
To examine the function of SOX12 in AML cells, THP1 cells were transduced with a lentivirus containing GFP-tagged SOX12 shRNAs. A lentiviral plasmid carrying the scrambled sequence was used as a control. The transduced THP1 cells were sorted by FACS according to GFP expression. SOX12 expression was confirmed by real-time PCR and Western blot analysis (Fig 3A & B) . The GFP + THP1 cells were cultured, and cell numbers were enumerated on subsequent days. In three independent experiments, SOX12 knockdown reduced THP1 cell growth in vitro (Fig 3C) . To confirm this finding, we analysed the proliferation of the transduced cells by quantifying 3 H thymidine incorporation and showed that 3 H thymidine uptake was significantly reduced in SOX12 knockdown cells (Fig 3D) , suggesting that SOX12 knockdown could inhibit THP1 cell proliferation. We further investigated the cell cycle profiles of the transduced cells. The results showed that more cells were in G 1 phase after SOX12 knockdown, and the number of cells in S and G 2 /M phases were decreased accordingly (Fig 3E) . This observation indicated that the reduced cell proliferation could be due to cell cycle arrest in G1 phase. However, SOX12 knockdown had no significant effect on apoptosis, which was confirmed by Annexin V/7AAD staining. The flow cytometric analysis showed that the 7AAD À Annexin V + populations in both the scramble-and SOX12 shRNAexpressing cells were similar (Fig 3F) . The effects of SOX12 expression on the differentiation and proliferation of leukaemia cells were further evaluated in transduced THP1 cells by a colony forming unit assay. The GFP + -transduced cells were cultured in methylcellulose medium for 13 days. The results showed that the frequency of colonies decreased significantly after SOX12 knockdown in THP1 cells (Fig 3G) . Together, these data showed that SOX12 knockdown in THP1 cells could reduce proliferation by trafficking cells in G1 phase rather than affecting apoptosis.
The repopulating potential of THP1 and primary AML cells in immunodeficient NOD/SCID mice was significantly impeded by SOX12 knockdown
To evaluate the effects of SOX12 on leukaemia progression, the repopulating potential of SOX12 shRNA-transduced myeloblasts in immunodeficient NOD/SCID mice was examined. Transduced THP1 cells (scramble or SOX12 shRNAs) were intravenously transplanted into sublethally irradiated NOD/ SCID mice. Six to 8 weeks after transplantation, the mice were sacrificed, and mouse bone marrow cells were harvested and subjected to FACS analysis. The results showed that the scramble-transduced THP1 cells repopulated the bone marrow with higher potential in the transplanted mice. In contrast, the repopulating capacities of SOX12 shRNAtransduced cells were significantly impaired (Fig 4A) . expressing viral particles. The transduced cells were selected based on GFP expression (range: 1-3 9 10 5 cells) and intravenously transplanted into sublethally irradiated NOD/SCID mice. Twelve weeks later, the mice were sacrificed, and the bone marrow cells were analysed. The results showed that SOX12 knockdown in AML cells significantly reduced leukaemia cell engraftment in NOD/SCID mice (Fig 4B) . SOX12 expression in AML cells was detected by qPCR before transplantation and after sacrifice of the mice by sorting the GFP+ cells (Fig 4C, D) .
b-catenin expression and TCF/Wnt activity were reduced following SOX12 knockdown
The Wnt-catenin pathway is one of the most important pathways in leukaemogenesis (Simon et al, 2005; Petropouls et al, 2008) , and several SOX genes participate in this pathway (Lin et al, 2013; Liu et al, 2014; Thu et al, 2014; Zhou et al, 2014; Man et al, 2015; Yang et al, 2015) . SOX12, a member of the SOX C subgroup, is involved in the Wnt/bcatenin pathway (Bhattaram et al, 2014; Duquet et al, 2014; Kato et al, 2015) . To investigate the role of SOX12 in AML, we examined the correlation between SOX12 expression and the activity of the Wnt/b-catenin pathway. Following SOX12 knockdown, CTNNB1 mRNA and CTNNB1 protein expression were significantly decreased in THP1 cells (Fig 5A & B) , accompanied by inhibition of TCF/Wnt activity ( Fig 5C) . However, transient transfection of CTNNB1 into THP1 cells with SOX12 knockdown by shRNA2 could rescue the TCF/ Wnt activity (Fig 5C) , indicating that SOX12 played a role in the Wnt/b-catenin pathway in AML cells by regulating bcatenin expression (Fig 5A-C) . Interestingly, despite the reported compensatory effects of SOX4 and SOX11 on the reduced expression of SOX12 during embryonic development, we could not detect any significant changes in SOX4 and SOX11 expression in THP1 cells (Fig 5D & E) . 
Discussion
This is the first study to investigate the pathogenesis and progression of AML in relation to SOX12. The results showed that SOX12 was highly expressed in AML, and SOX12 knockdown could inhibit leukaemia cell proliferation and leukaemia initiation in a mouse model. SOX12 knockdown was associated with a decrease in b-catenin expression, aberrant nuclear translocation and decreased TCF/Wnt activity.
The expression of the SoxC subgroup of genes in mouse embryos is widespread and largely overlapping (Dy et al, 2008) . We found that SOX12 expression was silenced in most normal bone marrow cells, which is consistent with a previous study showing that SoxC gene expression is restricted at birth and that SOX12 is expressed at low levels in most adult human tissues (Jay et al, 1997) . However, SOX12 was highly expressed in AML patients. A previous gene expression profile of the SOX family in leukaemia showed that SOX12 was highly expressed in malignant leukaemia, including AML, myelodysplastic syndrome, chronic myeloid leukaemia, precursor B-cell acute lymphoblastic leukaemia (Haixia Wan, Jiayi Cai, Fangyuan Chen, Jianyi Zhu, Jihua Zhong and Hua Zhong, unpublished data) , mantle cell lymphoma, human hepatocellular carcinoma and colon cancer (Wasik et al, 2013; Duquet et al, 2014; Huang et al, 2015) . These data indicated that the SOX12 expression profile in leukaemia cells differed from that of normal tissues. In addition, unlike the findings during embryonic development (Hoser et al, 2008) , we did not observe any dramatic increase in SOX4 and SOX11 expression to compensate for the decrease in SOX12 expression. Normal haematopoiesis is organized as a hierarchy with haematopoietic stem cells at the apex and differentiated blood cells at the base. AML is organized in a similar manner, in which LICs are critical for the progression of AML (Bonnet & Dick, 1997) . Hence, an understanding of the molecular characteristics of LICs is important for the cure of this disease. We found that SOX12 was preferentially expressed in CD34 + cells, which were enriched in of LICs in AML (Bonnet & Dick, 1997; Schubert et al, 2011) , indicating that SOX12 might be an important marker of LICs or leukaemic progenitors. However, we did not observe any significant difference in SOX12 expression between the CD34 + CD38 À and CD34 + CD38 + subpopulations, although the LICs were present in the CD34 + CD38 À fraction but not the CD34 + CD38 + fraction (Lapidot et al, 1994) . This could be a consequence of the small sample size assessed in this study.
To further investigate the correlation between SOX12 and AML, SOX12 expression was knocked down in THP1 cells or primary AML cells with a lentivirus containing shRNAs. The results showed that SOX12 knockdown inhibited cell proliferation and reduced the clonogenicity and leukaemia propagation of THP1 cells and AML myeloblasts, indicating that SOX12 played an important role in maintaining the function of AML cells. These effects were associated with a cell cycle delay in G1 phase without affecting apoptosis, suggesting that SOX12 knockdown specifically induced anti-proliferative but not cytotoxic effects. Previous studies have shown that SOX12 knockdown can increase metastatic growth after direct seeding, without affecting the proliferation of colon cancer cells (Duquet et al, 2014) . However, in hepatocellular carcinoma, SOX12 knockdown could dramatically decrease the growth of cancer cells without significantly affecting apoptosis (Huang et al, 2015) , which is similar to our present findings.
The Wnt/b-catenin pathway is an evolutionarily highly conserved signalling cascade that is critical for normal embryogenesis and haematopoiesis (Kielman et al, 2002; Sato et al, 2004) . Wnt inhibitor proteins function through both the canonical (b-catenin mediated) and non-canonical (Wnt Ca ++ pathway, Wnt planar cell polarity pathway) pathways, which are critical for cell fate determination, proliferation, and gene expression (Moon et al, 2002; Khan & Bendall, 2006; Katoh & Katoh, 2007) . Aberrant activation of this pathway might lead to pathogenesis. SOX genes can be either activators or inhibitors of the Wnt pathway (Sinner et al, 2007) . In our study, b-catenin expression was decreased following SOX12 knockdown, which was accompanied by a significant reduction of TCF/Wnt activity. However, the introduction of CTNNB1 into THP1 cells restored TCF/Wnt activity, indicating that the pathological function of SOX12 (Zhang et al, 2009; Man et al, 2015) , the mechanisms by which SOX12 regulates the expression of b-catenin remain to be elucidated.
In conclusion, we demonstrated the pathogenic effects of SOX12 in AML, facilitating the identification of specific factors related to the characteristics of LICs and leukaemia progression, which may be critical for the development of a new treatment strategy for AML.
